Paclitaxel binding to human serum albumin—Automated docking studies Original Research Article

A computational approach was used to study the interaction of the potent anticancer drug paclitaxel (Taxol®) with human serum albumin. The primary and secondary binding sites were located at the interface of subdomains IIA and IIIA, and in the cleft between domains I and III of the protein, respectively. The C13 side chain and the baccatin core of paclitaxel were found to contribute approximately equally to the binding energy at the primary site, whereas the binding mode appears to be governed by the C13 side chain.